Literature DB >> 9395350

Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics.

A Marx1, T J Török, R C Holman, M J Clarke, L J Anderson.   

Abstract

Croup is a common manifestation of respiratory tract infection in children, and human parainfluenza virus 1 (HPIV-1) is the agent most commonly associated with croup. In the United States, HPIV-1 produces a distinctive pattern of biennial epidemics of respiratory illness during the autumn months of odd-numbered years. National Hospital Discharge Survey data for croup hospitalizations among patients <15 years old between 1979 and 1993 were examined along with laboratory-based surveillance data on HPIV-1 activity in the United States. The mean annual number of croup hospitalizations was 41,000 (range, 27,000-62,000/year). Ninety-one percent of hospitalizations occurred among children <5 years of age. Minor peaks in croup hospitalizations occurred each year in February, and major peaks occurred in October of odd-numbered years, coincident with peak HPIV-1 activity. Each biennial epidemic of HPIV-1 was associated with 18,000 excess croup hospitalizations nationwide.

Entities:  

Mesh:

Year:  1997        PMID: 9395350     DOI: 10.1086/514137

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  55 in total

1.  Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.

Authors:  Josephine M McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.

Authors:  J E Bailly; J M McAuliffe; A P Durbin; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 3.  Croup in children.

Authors:  Candice L Bjornson; David W Johnson
Journal:  CMAJ       Date:  2013-08-12       Impact factor: 8.262

4.  Glucocorticoids in the treatment of croup: barking up the right tree.

Authors:  T P Klassen
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

5.  Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.

Authors:  T Tao; A P Durbin; S S Whitehead; F Davoodi; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.

Authors:  J E Bailly; J M McAuliffe; M H Skiadopoulos; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

Review 7.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

8.  Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975-1997.

Authors:  H Laurichesse; D Dedman; J M Watson; M C Zambon
Journal:  Eur J Epidemiol       Date:  1999-05       Impact factor: 8.082

9.  Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.

Authors:  Irina V Alymova; Garry Taylor; Toru Takimoto; Tsu-Hsing Lin; Pooran Chand; Y Sudhakara Babu; Chenghong Li; Xiaoping Xiong; Allen Portner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Authors:  Irina V Alymova; Garry Taylor; Vasiliy P Mishin; Makiko Watanabe; K Gopal Murti; Kelli Boyd; Pooran Chand; Y Sudhakara Babu; Allen Portner
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.